Progesterone receptor antagonists

US8969328B2 · kind B2 · utility

Assignee

• Bayer Intellectual Property GmbH · DE

Inventors

• Wolfgang Schwede · Berlin, DE
• Ulrich Klar · Berlin, DE
• Carsten Möller · Berlin, DE
• Andrea Rotgeri · Berlin, DE
• Wilhelm Bone · Berlin, DE
• Christoph Huwe · Berlin, DE

Key dates

• Filing date: Feb 8, 2011
• Grant date: Mar 3, 2015
• Expiry date: Nov 20, 2031

Classification

• Technology area (CPC —): General

Abstract

The invention relates to 17-hydroxy-17-pentafluoroethyl-estra-4,9(10)-dien-11-aryl derivatives of formula I with progesterone-antagonizing action and methods of production thereof, use thereof for the treatment and/or prevention of diseases and use thereof for producing medicinal products for the treatment and/or prevention of diseases, in particular uterine fibroids (myomata, uterine leiomyomata), endometriosis, heavy menstrual bleeding, meningiomata, hormone-dependent breast cancers and menopause-associated complaints or for fertility control and emergency contraception.